Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment (UPA-MEST)
Primary Hyperaldosteronism Due to Adrenal Adenoma
About this trial
This is an interventional treatment trial for Primary Hyperaldosteronism Due to Adrenal Adenoma focused on measuring hyperaldosteronism, primary aldosteronism, lateralized aldosteronism, unilateral aldosteronism, eplerenone, spironolactone, randomized trial, quality of life, PASO outcomes
Eligibility Criteria
Inclusion Criteria: Patients with confirmed unilateral PA Age 18-70 years Candidate for surgical treatment No contraindications for minimally invasive surgery or treatment with MRA Understands oral and written information and provides oral and written informed consent. Exclusion Criteria: Unwilling or unable to undergo surgery Unwilling to accept medical treatment for 12 months and not receiving standard treatment (surgery) Impaired renal function with eGFR <45 ml/min/1,73m2 P-cortisol >138 nmol/L following 1-mg overnight dexamethasone suppression test.
Sites / Locations
- University of GothenburgRecruiting
- Karolinska University Hospital, Stockholm, Sweden.
- Umeå University, Umeå, Sweden.
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Surgically Treated Primary Aldosteronism
Medically Treated Unilateral Primary Aldosteronism
Standard therapy
Open label eplerenone treatment